“DISE is effective against all cancers we tested.” Credit: 2023 Patel and Peter. “DISE is effective against all cancers we tested.” A new editorial...
ATLANTA—An oral lipid nanoparticle drug prevents tumor development in mice, suggesting this is a promising drug formulation for preventing colitis-associated...
LAB eN2 will be based in Cambridge, MA, part of the Greater Boston region where Novo has anchored—and earlier this year announced plans to expand—its...
Researchers at UMass Chan Medical School have developed a small interfering RNA (siRNA) technology that is stable enough for inhalation into the lungs,...
Cancer is a complex systemic disease, with accompanying secondary effects that can result in debilitating effects on the human body. Cancer-associated...
Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could The post Taking an ‘upside-down’ approach...
Back in October, when small interfering RNA player Sirnaomics landed its Series D round, CEO Patrick Lu said he was open to preparing for an IPO...
Credit: The University of Texas at Austin Viruses attack the body by sending their genetic code — DNA and RNA — into cells and multiplying. A...
Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start The post Cash round sets up trial of...
Researchers take a step in the development of genome editing technology. Credit: Peter the Great St.Petersburg Polytechnic University Researchers from Peter the Great St.Petersburg Polytechnic University...
Promising mRNA tech comes with regulatory, CMC headaches
Genetic Engineering, No Virus Required
Biotech Bonanza – Second Half Outlook 2020